| . | Eplerenone (N = 149) . | Placebo (N = 151) . | Hazard ratio . |
|---|---|---|---|
| Primary endpoint | |||
| Cardiovascular death or a first re-hospitalization due to any cardiovascular disease | 29 (19.5%) | 26 (17.2%) | 1.09 (0.642–1.855) |
| Components of primary endpoint | |||
| HF | 6 (4.0%) | 11 (7.3%) | |
| STEMI | 0 | 1 (0.7%) | |
| Valvular diseases | 1 (0.7%) | 1 (0.7%) | |
| Stroke | 2 (1.3%) | 2 (1.3%) | |
| Ventricular arrhythmia | 2 (1.3%) | 1 (0.7%) | |
| Atrial fibrillation | 2 (1.3%) | 0 | |
| Left ventricular thrombus | 0 | 1 (0.7%) | |
| Coronary artery disease | 16 (10.7%) | 9 (6.0%) | |
| Secondary endpoint | |||
| Cardiovascular death or a first re-hospitalization due to HF | 7 (4.7%) | 11 (7.3%) | 0.55 (0.213–1.434) |
| Cardiovascular death or non-fatal AMI | 2 (1.3%) | 1 (0.7%) | 1.88 (0.170–20.747) |
| First re-hospitalization due to any cardiovascular disease | 29 (19.5%) | 26 (17.2%) | 1.09 (0.642–1.855) |
| Death from any cardiovascular disease | 2 (1.3%) | 0 (0.0%) | |
| First re-hospitalization due to HF | 7 (4.7%) | 11 (7.3%) | 0.55 (0.213–1.434) |
| Death from any cause | 2 (1.3%) | 0 (0.0%) | |
| Non-fatal AMI | 0 (0.0%) | 1 (0.7%) | |
| Cardiac sudden death | 0 (0.0%) | 0 (0.0%) | |
| Therapy with medical device for HF | 4 (2.7%) | 9 (6.0%) | 0.39 (0.120–1.278) |
| . | Eplerenone (N = 149) . | Placebo (N = 151) . | Hazard ratio . |
|---|---|---|---|
| Primary endpoint | |||
| Cardiovascular death or a first re-hospitalization due to any cardiovascular disease | 29 (19.5%) | 26 (17.2%) | 1.09 (0.642–1.855) |
| Components of primary endpoint | |||
| HF | 6 (4.0%) | 11 (7.3%) | |
| STEMI | 0 | 1 (0.7%) | |
| Valvular diseases | 1 (0.7%) | 1 (0.7%) | |
| Stroke | 2 (1.3%) | 2 (1.3%) | |
| Ventricular arrhythmia | 2 (1.3%) | 1 (0.7%) | |
| Atrial fibrillation | 2 (1.3%) | 0 | |
| Left ventricular thrombus | 0 | 1 (0.7%) | |
| Coronary artery disease | 16 (10.7%) | 9 (6.0%) | |
| Secondary endpoint | |||
| Cardiovascular death or a first re-hospitalization due to HF | 7 (4.7%) | 11 (7.3%) | 0.55 (0.213–1.434) |
| Cardiovascular death or non-fatal AMI | 2 (1.3%) | 1 (0.7%) | 1.88 (0.170–20.747) |
| First re-hospitalization due to any cardiovascular disease | 29 (19.5%) | 26 (17.2%) | 1.09 (0.642–1.855) |
| Death from any cardiovascular disease | 2 (1.3%) | 0 (0.0%) | |
| First re-hospitalization due to HF | 7 (4.7%) | 11 (7.3%) | 0.55 (0.213–1.434) |
| Death from any cause | 2 (1.3%) | 0 (0.0%) | |
| Non-fatal AMI | 0 (0.0%) | 1 (0.7%) | |
| Cardiac sudden death | 0 (0.0%) | 0 (0.0%) | |
| Therapy with medical device for HF | 4 (2.7%) | 9 (6.0%) | 0.39 (0.120–1.278) |
AMI, acute myocardial infarction; HF, heart failure; STEMI, ST-segment elevation myocardial infarction.
| . | Eplerenone (N = 149) . | Placebo (N = 151) . | Hazard ratio . |
|---|---|---|---|
| Primary endpoint | |||
| Cardiovascular death or a first re-hospitalization due to any cardiovascular disease | 29 (19.5%) | 26 (17.2%) | 1.09 (0.642–1.855) |
| Components of primary endpoint | |||
| HF | 6 (4.0%) | 11 (7.3%) | |
| STEMI | 0 | 1 (0.7%) | |
| Valvular diseases | 1 (0.7%) | 1 (0.7%) | |
| Stroke | 2 (1.3%) | 2 (1.3%) | |
| Ventricular arrhythmia | 2 (1.3%) | 1 (0.7%) | |
| Atrial fibrillation | 2 (1.3%) | 0 | |
| Left ventricular thrombus | 0 | 1 (0.7%) | |
| Coronary artery disease | 16 (10.7%) | 9 (6.0%) | |
| Secondary endpoint | |||
| Cardiovascular death or a first re-hospitalization due to HF | 7 (4.7%) | 11 (7.3%) | 0.55 (0.213–1.434) |
| Cardiovascular death or non-fatal AMI | 2 (1.3%) | 1 (0.7%) | 1.88 (0.170–20.747) |
| First re-hospitalization due to any cardiovascular disease | 29 (19.5%) | 26 (17.2%) | 1.09 (0.642–1.855) |
| Death from any cardiovascular disease | 2 (1.3%) | 0 (0.0%) | |
| First re-hospitalization due to HF | 7 (4.7%) | 11 (7.3%) | 0.55 (0.213–1.434) |
| Death from any cause | 2 (1.3%) | 0 (0.0%) | |
| Non-fatal AMI | 0 (0.0%) | 1 (0.7%) | |
| Cardiac sudden death | 0 (0.0%) | 0 (0.0%) | |
| Therapy with medical device for HF | 4 (2.7%) | 9 (6.0%) | 0.39 (0.120–1.278) |
| . | Eplerenone (N = 149) . | Placebo (N = 151) . | Hazard ratio . |
|---|---|---|---|
| Primary endpoint | |||
| Cardiovascular death or a first re-hospitalization due to any cardiovascular disease | 29 (19.5%) | 26 (17.2%) | 1.09 (0.642–1.855) |
| Components of primary endpoint | |||
| HF | 6 (4.0%) | 11 (7.3%) | |
| STEMI | 0 | 1 (0.7%) | |
| Valvular diseases | 1 (0.7%) | 1 (0.7%) | |
| Stroke | 2 (1.3%) | 2 (1.3%) | |
| Ventricular arrhythmia | 2 (1.3%) | 1 (0.7%) | |
| Atrial fibrillation | 2 (1.3%) | 0 | |
| Left ventricular thrombus | 0 | 1 (0.7%) | |
| Coronary artery disease | 16 (10.7%) | 9 (6.0%) | |
| Secondary endpoint | |||
| Cardiovascular death or a first re-hospitalization due to HF | 7 (4.7%) | 11 (7.3%) | 0.55 (0.213–1.434) |
| Cardiovascular death or non-fatal AMI | 2 (1.3%) | 1 (0.7%) | 1.88 (0.170–20.747) |
| First re-hospitalization due to any cardiovascular disease | 29 (19.5%) | 26 (17.2%) | 1.09 (0.642–1.855) |
| Death from any cardiovascular disease | 2 (1.3%) | 0 (0.0%) | |
| First re-hospitalization due to HF | 7 (4.7%) | 11 (7.3%) | 0.55 (0.213–1.434) |
| Death from any cause | 2 (1.3%) | 0 (0.0%) | |
| Non-fatal AMI | 0 (0.0%) | 1 (0.7%) | |
| Cardiac sudden death | 0 (0.0%) | 0 (0.0%) | |
| Therapy with medical device for HF | 4 (2.7%) | 9 (6.0%) | 0.39 (0.120–1.278) |
AMI, acute myocardial infarction; HF, heart failure; STEMI, ST-segment elevation myocardial infarction.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
